Deltyba: new antibacterial for multidrug-resistant tuberculosis

Otsuka Novel Products has launched Deltyba (delamanid) for use as combination therapy for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults where other agents cannot be used owing to resistance or intolerance.

 Deltyba (delamanid) should be given as directly observed therapy at a dose of 100mg (two tablets) twice daily with food for 6 months.
Deltyba (delamanid) should be given as directly observed therapy at a dose of 100mg (two tablets) twice daily with food for 6 months.

Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits mycolic acid synthesis and has potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.

A randomised, placebo-controlled trial in 481 patients with pulmonary multidrug-resistant tuberculosis showed that addition of delamanid 100mg twice daily to background therapy increased the sputum-culture conversion rate (as assessed in liquid broth medium) at 2 months to 45.4%, compared with 29.6% for addition of placebo (p=0.008). 

In an observational follow-up study in 421 participants, the rate of favourable outcomes (cure or treatment completion) at 24 months was significantly higher in those who received delamanid for ≥6 months than in those who were treated for ≤2 months (74.5% vs 55%; RR 1.35 [95% CI 1.17–1.56], p<0.001). Mortality rates were also significantly reduced with extended treatment (1.0% vs 8.3%, p<0.001). 

The most frequently reported adverse effects of delamanid were nausea, vomiting and dizziness. However, QT interval prolongation was the most notable safety concern.

The recommended dose for adults is 100mg twice daily for 24 weeks.

View Deltyba drug record

Further information: Otsuka Novel Products

Follow MIMS on Twitter

Sign up for MIMS bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases